Skip to main content

Table 4 Multivariate model for overall survival for chemotherapy cohort (n = 4102)

From: Sidedness is prognostic in locoregional colon cancer: an analysis of 9509 Australian patients

Characteristic Stage II (n = 1631) Stage III (n = 2441)
Multivariate Multivariate
HR (95% CI) HR (95% CI)
Sided Left 1 1
Right 0.86 (0.68–1.09) 1.29 (1.11–1.50)
Age ≤60 1 1
61–70 1.90 (1.20–2.99) 1.21 (0.94–1.54)
71–80 2.97 (1.92–4.58) 1.81 (1.43–2.30)
>80 5.92 (3.82–9.19) 2.00 (1.54–2.60)
Grade Well/mod differentiated 1 1
Poorly Differentiated 1.43 (1.08–1.90) 1.49 (1.26–1.75)
TNM stage IIIa 1 1
IIIb 2.20 (1.71–2.82)a 1.79 (1.33–2.43)
IIIc - 3.86 (2.84–5.24)
Sex Male 1 1
Female 0.85 (0.68–1.07) 0.94 (0.82–1.10)
CCI 0 1 1
1–2 1.42 (1.09–1.52) 1.15 (0.96–1.38)
3–4 1.60 (1.12–2.28) 1.20 (0.94–1.53)
5 2.31 (1.45–3.69) 1.83 (1.36–2.46)
Year Diagnosed 2006–2009 1 1
2010–2013 0.99 (0.79–1.26) 1.00 (0.86–1.17)
Adjuvant Chemotherapy Nil 1 1
Fluorouracil monotherapy 0.79 (0.51–1.10)b 0.48 (0.40–0.57)
Oxaliplatin doublet - 0.38 (0.27–0.42)
  1. HR Hazard Ratio, CI confidence interval, CCI Charlson Comorbity index
  2. aIIa vs IIb/IIc, bchemotherapy vs no chemotherapy